Results 221 to 230 of about 86,630 (338)

Novel Activity of Oral Hypoglycemic Agents Linked with Decreased Formation of Tryptophan Metabolite, Kynurenic Acid. [PDF]

Life (Basel)
Bednarz K, Kozieł K, Urbańska EM.
europepmc   +1 more source

Preferences for basal insulin treatments in adults with type 2 diabetes: A discrete choice experiment in France and Spain

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim To quantify the relative importance of frequency of administration in basal insulin treatment preferences of people living with type 2 diabetes (T2D) in France and Spain, using a discrete choice experiment (DCE). Materials and Methods A targeted literature review and qualitative patient interviews informed an attributes and levels grid ...
Amy M. Jones, Pam Hallworth, Helen Kendal, Claire Mottershead, Lewis Ormerod, Virginia Pascual, Clémence Antier, Diogo Belbute, Elisabeth de Laguiche, Virginia Bellido   +9 more
wiley   +1 more source

Disparity in cost of oral hypoglycemic agents available in Indian market

, 2019
Dheeraj Kumar Singh, Mukesh Kumar, Soni Soni   +2 more
openalex   +2 more sources

Physiological Effect of Quercetin as a Natural Flavonoid to be used as Hypoglycemic Agent in Diabetes Mellitus Type II Rats

, 2021
Osama A. Shaikhomar, Omar Bahattab
openalex   +1 more source

Long‐term effects of a multidomain intervention on cognitive function and metabolic control in older adults with type 2 diabetes and mild cognitive impairment: A 42‐month follow‐up of the J‐MIND‐Diabetes study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This study investigated the long‐term effects of a multidomain intervention on cognition and metabolic control in patients with type 2 diabetes and mild cognitive impairment (MCI). Materials and methods Outpatients aged 70–85 years were randomized to an 18‐month multidomain intervention (comprising metabolic/vascular risk management ...
Taiki Sugimoto, Takuya Omura, Atsushi Araki, Chie Haneda, Keiko Honda, Minoru Kishi, Toshimasa Takahashi, Kenji Toyoshima, Suguru Tsuume, Kazuaki Uchida, Hisashi Noma, Ayaka Onoyama, Yoko Yokoyama, Mio Shinozaki, Paul K. Crane, Takashi Sakurai, J‐MIND‐Diabetes Study Group   +16 more
wiley   +1 more source

Comparative evaluation of biphasic insulin with metformin and triple oral hypoglycemic agents (OHA) in type 2 diabetes patients. [PDF]

Saudi Pharm J, 2020
Alavudeen SS, Khobrani M, Dhanapal CK, Mir JI, Alshahrani SM, Khan NA, Alhossan A.   +6 more
europepmc   +1 more source

Action of the oral hypoglycemic agent 2-tetradecylglycidic acid on hepatic fatty acid oxidation and gluconeogenesis.

, 1979
Gene F. Tutwiler, P. Dellevigne
openalex   +1 more source

Dual action of imeglimin on insulin secretion and sensitivity in type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Imeglimin is a novel oral hypoglycemic agent approved for the treatment of type 2 diabetes in Japan, with dual actions to enhance insulin secretion and improve insulin sensitivity, suggested by preclinical evidence. However, the effect of imeglimin on tissue‐specific insulin sensitivity and glucose kinetics using glucose tracers is ...
Tsubasa Tajima, Hideyoshi Kaga, Naoaki Ito, Toshiki Kogai, Hitoshi Naito, Saori Kakehi, Satoshi Kadowaki, Yuya Nishida, Ryuzo Kawamori, Yoshifumi Tamura, Hirotaka Watada   +10 more
wiley   +1 more source

Effectiveness of Jena DM® Herbal Formulation as Complementary Therapy to Conventional Oral Hypoglycemic Agents in Type-2 Diabetes Mellitus: A Quasi-experimental Study. [PDF]

Cureus
Kiptoo J, Mekuriya Yadesa T, Ajayi CO, Kushemererwa O, Kantengwa A, Muyingo A.   +5 more
europepmc   +1 more source